Hair loss is a reported adverse reaction with Zepbound, the FDA-approved injection containing tirzepatide. Its prescribing information links those reports to weight reduction. That does not establish why your hair is shedding, whether the medicine is the direct cause, or how your hair will recover. Zepbound prescribing information, section 6.1.
The useful next step is to describe the timing and pattern to your prescribing clinician. A dermatologist can help distinguish excessive shedding from other forms of hair loss; more than one cause can be present. American Academy of Dermatology: hair loss or hair shedding.
You do not need to wait until thinning is dramatic to ask for an assessment. Hair changes can be upsetting, and your concern deserves attention even when there is no painful scalp symptom.
What do the Zepbound and Mounjaro labels actually show?
We checked both products' August 2026 prescribing information on October 10, 2026. Both injections contain tirzepatide, but their adverse-reaction tables describe different studied populations.
| Product and evidence | What the label reports about hair loss | Important limit |
|---|---|---|
| Zepbound: two pooled weight-reduction trials in adults with obesity or overweight, with or without type 2 diabetes | Hair loss was reported more frequently in treated groups than with placebo and was associated with weight reduction | A reported event does not identify the cause in an individual or establish a recovery timeline |
| Mounjaro: common trial reactions in adults with type 2 diabetes, plus separate postmarketing reports | Hair loss is absent from the common-adverse-reaction table; section 6.2 separately lists alopecia after approval | These voluntary reports come from a population of uncertain size, so it is not always possible to estimate their frequency reliably or establish a causal relationship. An absent trial-table entry is not zero risk |
Sources: Zepbound prescribing information, section 6.1, Table 1 and Hair Loss; Mounjaro prescribing information, sections 6.1 and 6.2.
Mounjaro's August 2026 label, section 6.2, lists alopecia among reactions reported after approval. These voluntary reports come from a population of uncertain size, so it is not always possible to estimate their frequency reliably or establish a causal relationship. This is a different kind of evidence from a controlled trial table. Mounjaro prescribing information, section 6.2.
The Zepbound label also reports more hair-loss events among female than male participants in both the Zepbound and placebo groups. That observation is not a prediction for any one person. These trial pools are not a comparison of the two brands, and their findings cannot establish the risk for a particular compounded preparation.
Why timing and weight changes matter
One possible explanation for shedding during weight loss is telogen effluvium, a form of excessive hair shedding after a stressor. The American Academy of Dermatology (AAD) describes significant weight loss, illness, surgery, childbirth, and major stress among possible triggers. Shedding can become noticeable a few months after the event. AAD: hair shedding.
That delay makes the preceding months useful to discuss, rather than only the day of your last administration. A prescription change, an illness, and a change in eating may have overlapping timelines. The sequence is information for an assessment, not a test that proves which event caused the shedding.
It would go beyond the evidence to say that every case on tirzepatide is telogen effluvium or that weight loss is the only explanation. Hereditary hair loss, thyroid disease, anemia, scalp conditions, other medicines, and hair practices can also be relevant. MedlinePlus: hair loss, Causes.
Hair shedding also cannot tell you whether tirzepatide is working. Neither checked label presents hair loss as a marker of treatment benefit. It is a concern to assess, not a goal or an expected sign of successful treatment.
Which hair or scalp changes should be assessed?
Arrange a clinical assessment if loss is patchy, rapidly increasing, or accompanied by scalp pain, itching, redness, scaling, or signs of infection. Loss of eyebrow or eyelash hair also deserves attention. These patterns should not be automatically assigned to weight loss or a medicine. MedlinePlus: When to Contact a Medical Professional, AAD: signs and symptoms of hair loss.
A widening part, a changing hairline, or shedding across the scalp are useful descriptions to bring to the visit. They do not diagnose the condition. A dermatologist can examine the scalp and assess whether different patterns coexist. AAD: diagnosis and treatment.
If eating has become difficult, tell your prescribing team about that as well. Contact your healthcare provider right away for nausea, vomiting, or diarrhea that does not go away, as both Medication Guides instruct. Do not treat persistent symptoms as something to tolerate for the sake of your hair or weight goals. Zepbound Medication Guide, Mounjaro Medication Guide.
This hair guide does not replace urgent drug warnings. Both Medication Guides instruct users to stop the medicine and call their provider right away for severe persistent abdominal pain, with or without nausea or vomiting, sometimes extending to the back. For signs of a serious allergic reaction, they instruct users to stop the medicine and get medical help right away. Signs include swelling of the face, lips, tongue, or throat; breathing or swallowing problems; severe rash or itching; fainting or dizziness; or a very rapid heartbeat. Zepbound Medication Guide, Mounjaro Medication Guide.
Anaphylaxis is a medical emergency. For severe allergic-reaction symptoms, call 911 or your local emergency number immediately. Do not wait for a routine reply. MedlinePlus: anaphylaxis.
Is hair loss on tirzepatide permanent?
The cause matters. General excessive shedding after a stressor often improves as the body readjusts, but an ongoing trigger can prolong it. Other conditions can have different courses. AAD explains that a dermatologist can distinguish shedding from hair loss, and some people have both. AAD: hair loss or hair shedding.
The checked tirzepatide labels do not give a universal time to regrowth or guarantee complete recovery. A general description of temporary shedding is not a tirzepatide-specific prognosis. Ask what pattern the clinician thinks is present, what would support that explanation, and what changes should lead to reassessment. Do not postpone an evaluation because an online timeline says to wait several months.
Can you prevent it or support your hair?
The sources checked here do not establish a method that reliably prevents hair loss during tirzepatide treatment. They do support attention to nutrition and hair care without promising that these measures will stop medication-associated shedding.
Tell your care team if reduced appetite, nausea, skipped meals, or added food restrictions make adequate eating difficult. AAD notes that insufficient calories, protein, or iron can contribute to hair loss. A clinician or registered dietitian can assess what your eating pattern needs; this article does not set a calorie limit, protein target, or supplement regimen. AAD: tips for managing hair loss.
Gentle care can help avoid adding damage: handle wet hair carefully, limit heat and harsh chemical treatments, and avoid hairstyles that pull tightly. These steps address breakage or traction; they are not a proven way to prevent telogen effluvium from treatment or weight changes. AAD: hair-care tips.
Before buying supplements or requesting tests
Hair loss does not establish a nutrient deficiency. AAD describes a history and examination first, with tests when the findings suggest an illness, deficiency, infection, or another specific cause. Everyone does not need the same laboratory panel. Ask what a proposed test would clarify and how the result would change your care. AAD: diagnosis and treatment.
Do not assume that a product marketed for hair growth addresses your situation. Excess amounts of some nutrients can worsen hair loss, and supplements should be matched to a demonstrated need rather than added automatically. AAD: managing hair loss.
NIH's Office of Dietary Supplements reports limited evidence for biotin's hair-health claims. Biotin-containing supplements can also interfere with some laboratory tests, including thyroid tests. Tell your clinician and the testing team what you take; let them give any preparation instructions. This article recommends no biotin dose, laboratory hold interval, shampoo, or hair-growth drug. NIH ODS: Biotin.
A timing and symptom worksheet for your visit
Use brief observations rather than trying to diagnose yourself or count every shed hair. Leave uncertain details blank. A record can organize the history your clinician reviews; it is not a diagnostic tool.
| What to record | Details to bring |
|---|---|
| Start and trend | When you first noticed a change; increasing, stable, or improving; whether it began before treatment |
| Pattern and scalp | Shedding throughout the scalp, a widening part, changing hairline, or patches; pain, itch, redness, scaling; eyebrow or eyelash changes |
| Earlier events | Illness, fever, surgery, childbirth, major stress, or noticeable weight changes in the preceding months |
| Eating and tolerance | Typical meals now; difficulty eating enough; nausea, vomiting, diarrhea, or new restrictions |
| Exact prescription | Medicine name and formulation, pharmacy label, start date, and recent prescription changes |
| Other exposures | Prescription and nonprescription medicines, vitamins, supplements, biotin-containing products, and hair-care changes |
The history fields draw on MedlinePlus: the hair-loss visit, AAD: assessment, and NIH: supplement disclosure. The prescription timeline is an additional practical detail to share with your prescriber.
You can send: “I use [exact medicine/formulation]. I noticed [pattern] starting [when]. It is [trend]. My scalp has [symptoms/no symptoms], and my eating or health has changed in these ways: [details]. Do I need a scalp assessment, nutrition review, or changes to my treatment plan?”
Ask whom to contact and when to review the trend. Do not delay needed medical help to finish the worksheet or wait for a routine message response.
What if the prescription is compounded tirzepatide?
The trial information above describes FDA-approved Zepbound and Mounjaro injections. It does not establish hair-loss frequency, recovery, safety, or dosing for a particular compounded preparation. Compounded drugs are not FDA approved, and FDA does not review them for safety, effectiveness, or quality before marketing. FDA: concerns about unapproved GLP-1 drugs.
Share the exact pharmacy label and formulation with your clinician. For hair-loss concerns, ask your prescriber to assess the treatment plan rather than creating your own pause, restart, or change. The urgent Medication Guide stop-use instructions above still apply to their specified warning symptoms.
This is general education for adults, not an individual diagnosis or a complete list of drug warnings. Related guides cover Zepbound side effects, tirzepatide nausea, and semaglutide hair loss. Evidence for another medicine should not be substituted for your own product's labeling.
Frequently Asked Questions
Does tirzepatide cause hair loss?
In Zepbound weight-reduction trials, hair loss was reported more often with treatment than with placebo, and the label associates it with weight reduction. Mounjaro lists alopecia among postmarketing reports. These voluntary reports come from a population of uncertain size, so it is not always possible to estimate their frequency reliably or establish a causal relationship. These findings do not establish the cause of an individual's shedding or predict recovery.
Is hair loss on tirzepatide permanent?
The cause determines the course. General shedding after a stressor can improve, while ongoing triggers or other hair-loss conditions can have a different course. The checked tirzepatide labels do not guarantee complete recovery or give a universal regrowth timeline.
When does shedding start, and how long does it last?
AAD describes shedding that becomes noticeable a few months after a stressor. That is general hair-shedding guidance, not a tirzepatide-specific schedule. Discuss the preceding months and the current trend with a clinician rather than using a timeline to delay assessment.
Can I prevent hair loss while taking tirzepatide?
The checked sources do not establish a method that reliably prevents it. Discuss difficulty eating enough and use gentle hair care to avoid additional damage. Neither step guarantees prevention or regrowth. Discuss supplements and prescription changes with your clinician; urgent Medication Guide instructions still apply.
Should I take biotin or request a hair-loss test panel?
Hair loss alone does not establish a deficiency, and everyone does not need the same tests. NIH reports limited evidence for biotin hair-health claims and warns about interference with some laboratory tests. Tell your clinician what you take and ask which evaluation fits your history.
When should I contact a clinician about hair loss?
Ask about new or bothersome shedding, especially if it is rapidly increasing, patchy, involves eyebrows or eyelashes, or comes with scalp pain, itching, redness, or scaling. These findings do not diagnose the cause. Severe medication-warning symptoms require the immediate help described in your Medication Guide.
Sources
This article is based on the following primary sources. Links open the original documents.
- 1.Zepbound prescribing information, revised August 2026 · Eli Lilly and Company · accessed
- 2.Mounjaro prescribing information, revised August 2026 · Eli Lilly and Company · accessed
- 3.Zepbound Medication Guide, revised August 2026 · Eli Lilly and Company · accessed
- 4.Mounjaro Medication Guide, revised August 2026 · Eli Lilly and Company · accessed
- 5.Do you have hair loss or hair shedding? · American Academy of Dermatology · accessed
- 6.Hair loss: Signs and symptoms · American Academy of Dermatology · accessed
- 7.Hair loss: Diagnosis and treatment · American Academy of Dermatology · accessed
- 8.Hair loss: Tips for managing · American Academy of Dermatology · accessed
- 9.Biotin: Fact Sheet for Consumers · National Institutes of Health, Office of Dietary Supplements · accessed
- 10.Hair loss · National Library of Medicine, MedlinePlus · accessed
- 11.FDA concerns about unapproved GLP-1 drugs · U.S. Food and Drug Administration · accessed
- 12.Anaphylaxis · National Library of Medicine, MedlinePlus · accessed
Telehealth prescribing rules differ by state. Read the state-by-state guide.
Majesta Health articles are written against primary sources (FDA labeling, NIH and CDC publications, state statutes) and each one passes a documented compliance review before publication. Where an article cites external sources, they are listed at the end of that article so you can check them yourself. No article currently carries an individual physician review; when a physician reviews an article, that page will show the reviewer's name, NPI and review date.
- Written against primary sources: FDA labeling and safety communications, NIH and CDC publications, state statutes and medical board rules
- Documented compliance review against FDA, FTC and LegitScript requirements before publication
- External sources, where an article cites them, are listed at the end of that article with links to the original documents
- Compounded medications are described as not FDA-approved as final products on every page that mentions them